Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells

Blood

Volumn 102, Issue 10, 2003, Pages 3815-3821

  Yvon, Eric S ^b   Vigouroux, Stephane ^b   Rousseau, Raphael F ^b   Biagi, Ettore ^b   Amrolia, Persis ^b   Dotti, Gianpietro ^b   Wagner, Hans Joachim ^b   Brenner, Malcolm K ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALLOANTIGEN; CD45 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 5; JAGGED1; NOTCH RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; EPSTEIN BARR VIRUS; GENE ACTIVATION; GENE OVEREXPRESSION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOREGULATION; INFECTION RISK; LYMPHOCYTE PROLIFERATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0242493801     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-12-3826     Document Type: Article

References (38)

1. Heslop HE. Haemopoietic stem cell transplantation from unrelated donors. Br J Haematol. 1999; 105:2-6.
2. Nakamura R, Bahceci E, Read EJ, et al. Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. Br J Haematol. 2001;115: 95-104.
3. Garderet L, Snell V, Przepiorka D, Schenk et al. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation. 1999;67:124-130.
4. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet. 2002; 360:130-137.
5. Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999;340: 1704-1714.
6. Artavanis-Tsakonas S, Matsuno K. Fortini ME. Notch signaling. Science. 1995;268:225-232.
7. Greenwald I, Rubin GM. Making a difference: the role of cell-cell interactions in establishing separate identities for equivalent cells. Cell. 1992;68: 271-281.
8. Pui JC, Allman D, Xu L, et al. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity. 1999; 11:299-308.
9. Robey E, Chang D, Itano A, et al. An activated form of Notch influences the choice between CD4 and CD8 T cell lineages. Cell. 1996;87:483-492.
10. Washburn T, Schweighoffer E, Gridley T, et al. Notch activity influences the alphabeta versus gammadelta T cell lineage decision. Cell. 1997; 88:833-843.
11. Hoyne GF, Le Roux I, Corsin-Jimenez M, et al. Serrate 1-induced notch signalling regulates the decision between immunity and tolerance made by peripheral CD4(+) T cells. Int Immunol. 2000; 12:177-185.
12. Yu X, Carpenter P, Anasetti C. Advances in transplantation tolerance. Lancet. 2001;357:1959-1963.
13. Roskrow MA, Suzuki N, Gan Y, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 1998;91:2925-2934.
14. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551-555.
15. Heinzinger M, Waller CF, von den Berg A, Rosenstiel A, Lange W. Generation of dendritic cells from patients with chronic myelogenous leukemia. Ann Hematol. 1999;78:181-186.
16. Eibl B, Ebner S, Duba C, et al. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response. Genes Chromosomes Cancer. 1997;20:215-223.
17. Varnum Finney B, Purton LE, Yu M, et al. The Notch ligand, Jagged-1, influences the development of primitive hematopoietic precursor cells. Blood. 1998;91:4084-4091.
18. Shayakhmetov DM, Lieber A. Dependence of adenovirus infectivity on length of the fiber shaft domain. J Virol. 2002;74:10274-10286.
19. Yotnda P, Onishi H, Heslop HE, et al. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001;8:930-937.
20. Lie YS, Petropoulos CJ. Advances in quantitative PCR technology: 5' nuclease assays. Curr Opin Biotech. 1998;9:43-48.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408.
22. Koenen HJ, Joosten I. Fine tuning of antigen-presenting cell-directed monoclonal antibody strategies in the induction of human allospecific T-cell tolerance in vitro. Transplant Proc. 1998;30:2447-2449.
23. Comoli P, Montagna D, Moretta A, Zecca M, Locatelli F, Maccario R. Alloantigen-induced human lymphocytes rendered nonresponsive by a combination of anti-CD80 monoclonal antibodies and cyclosporin-A suppress mixed lymphocyte reaction in vitro. J Immunol. 1995;155:5506-5511.
24. Jarriault S, Le Bail O, Hirsinger E, et al. Delta-1 activation of notch-1 signaling results in HES-1 transactivation. Mol Cell Biol. 1998;18:7423-7431.
25. Yamamoto N, Yamamoto S, Inagaki F, et al. Role of Deltex-1 as a transcriptional regulator down-stream of the Notch receptor. J Biol Chem. 2001; 276:45031-45040.
26. Ng WF, Duggan PJ, Ponchel F, et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood. 2001;98: 2736-2744.
27. Bertrand FE, Eckfeldt CE, Lysholm AS, LeBien TW. Notch-1 and Notch-2 exhibit unique patterns of expression in human B-lineage cells. Leukemia. 2000;14:2095-2102.
28. Felli MP, Maroder M, Mitsiadis TA, et al. Expression pattern of notch 1, 2 and 3 and Jagged1 and 2 in lymphoid and stromal thymus components: distinct ligand-receptor interactions in intrathymic T cell development. Int Immunol. 1999;11:1017-1025.
29. Anderson G, Pongracz J, Parnell S, Jenkinson EJ. Notch ligand-bearing thymic epithelial cells initiate and sustain Notch signaling in thymocytes independently of T cell receptor signaling. Eur J Immunol. 2001;31:3349-3354.
30. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101: 455-458.
31. Itoh M, Takahashi T, Sakaguchi N, et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol. 1999;162:5317-5326.
32. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001;193: 1303-1310.
33. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood. 2002; 100: 174-177.
34. Stephens LA, Mason D. CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25- subpopulations. J Immunol. 2000;165:3105-3110.
35. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev. 2001;182:207-214.
36. Piccirillo CA, Letterio JJ, Thornton AM, et al. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J Exp Med. 2002;196:237-246.
37. Waldmann H. Transplantation tolerance-where do we stand? Nat Med. 1999;5:1245-1248.
38. Salama AD, Remuzzi G, Harmon WE, Sayegh MH. Challenges to achieving clinical transplantation tolerance. J Clin Invest. 2001;108:943-948.